Forecasting of Emerging Therapeutic Monoclonal Antibodies Patents Based on a Decision Model
Published In
Technological Forecasting and Social Change
Document Type
Citation
Publication Date
2-1-2019
Abstract
Therapeutic monoclonal antibodies (mAbs) market is strongly contributing to the rising growth of the biotechnology industry. Despite the increasing number of inventions over time, a few therapeutic mAbs are currently marketed. This paper focuses on developing an emerging score to select/rank promising therapeutic mAbs patents, based on a hierarchical decision model using expert's opinion. Six attributes related to each factor concerning patent status, patent owner's profile and mAbs medical relevance were analyzed. The desirability levels of each attribute were also assessed. Our data shows the medical relevance factor as the most important, contributing 50% of the emerging score. Among the attributes, the most important under patent status was proper geographic coverage and wider patent scope; for organization's profile was the preexistence of approved drugs; and for medical relevance, the clinical phase performance. A group of 1053 patents related to therapeutic mAb were scored, and the most promising were concerning combination therapy using immune checkpoint inhibitors. The study has managerial implications related to patent portfolio management and patent valuation, and provides instructions to rank mAbs patents according to the emerging score defined by attribute's importance in order to improve the identification of future innovations pathways.
Locate the Document
DOI
10.1016/j.techfore.2018.11.002
Persistent Identifier
https://archives.pdx.edu/ds/psu/27900
Citation Details
Pereira, C. G., Lavoie, J. R., Garces, E., Basso, F., Dabić, M., Porto, G. S., & Daim, T. (2019). Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model. Technological Forecasting and Social Change, 139, 185-199.